Resistance looms for KRAS G12C inhibitors and rational tackling strategies
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Resistance looms for KRAS G12C inhibitors and rational tackling strategies
Authors
Keywords
KRAS, Resistance, Targeted therapy, Cancer, Secondary mutations, Covalent inhibitors
Journal
PHARMACOLOGY & THERAPEUTICS
Volume 229, Issue -, Pages 108050
Publisher
Elsevier BV
Online
2021-12-03
DOI
10.1016/j.pharmthera.2021.108050
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Importance of Ras in Drug Resistance in Cancer
- (2021) Fiona M. Healy et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cell-type Specific Adaptive Signaling Responses to KRASG12C inhibition
- (2021) Eric B Haura et al. CLINICAL CANCER RESEARCH
- Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy
- (2021) Jumin Huang et al. GUT
- Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor
- (2021) Malcolm P. Huestis et al. JOURNAL OF MEDICINAL CHEMISTRY
- Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS
- (2021) Erin Sheffels et al. JOURNAL OF MEDICINAL CHEMISTRY
- KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from the in vitro experiments
- (2021) Takamasa Koga et al. Journal of Thoracic Oncology
- RAS-targeted therapies
- (2021) Amanda R. Moore et al. NATURE REVIEWS DRUG DISCOVERY
- Mechanisms of Resistance to KRASG12C-Targeted Therapy
- (2021) Neal S. Akhave et al. Cancer Discovery
- Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches
- (2021) M. Reck et al. ANNALS OF ONCOLOGY
- The promise and peril of KRAS G12C inhibitors
- (2021) Amanda R. Moore et al. CANCER CELL
- The KRAS-G12C inhibitor: activity and resistance
- (2021) Jiao Liu et al. CANCER GENE THERAPY
- Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer
- (2021) Ze-Bo Jiang et al. CANCER LETTERS
- Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations
- (2021) Paul Yenerall et al. CANCER RESEARCH
- Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment
- (2021) D. Lucas Kerr et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Targeting mutant KRAS
- (2021) Daniel A. Erlanson et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Targeting Son of Sevenless 1: The pacemaker of KRAS
- (2021) Dirk Kessler et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation
- (2021) Ferdinandos Skoulidis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired Resistance to KRASG12C Inhibition in Cancer
- (2021) Mark M. Awad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling
- (2021) Baoyuan Zhang et al. Advanced Science
- KRAS G12C Mutations in NSCLC: From Target to Resistance
- (2021) Alfredo Addeo et al. Cancers
- Stopping the beating heart of cancer: KRAS reviewed
- (2021) Lorenz Herdeis et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
- (2021) Colin R. Lindsay et al. LUNG CANCER
- Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
- (2021) Daolin Tang et al. Molecular Cancer
- Diverse alterations associated with resistance to KRAS(G12C) inhibition
- (2021) Yulei Zhao et al. NATURE
- Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers
- (2020) Suman Mukhopadhyay et al. CANCER RESEARCH
- A Deep Learning Approach to Antibiotic Discovery
- (2020) Jonathan M. Stokes et al. CELL
- A06 Tri-complex Inhibitors of the Oncogenic, GTP-Bound Form of KRASG12C Overcome RTK-Mediated Escape Mechanisms and Drive Tumor Regressions in Preclinical Models of NSCLC
- (2020) R. Nichols et al. Journal of Thoracic Oncology
- A12 The SHP2 Inhibitor RMC-4630 in Patients with KRAS-Mutant Non-Small Cell Lung Cancer: Preliminary Evaluation of a First-in-Man Phase 1 Clinical Trial
- (2020) S.I. Ou et al. Journal of Thoracic Oncology
- Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
- (2020) Jenny Y. Xue et al. NATURE
- Resistance looms for KRASG12C inhibitors
- (2020) Aaron N. Hata et al. NATURE MEDICINE
- Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
- (2020) Louis Buscail et al. Nature Reviews Gastroenterology & Hepatology
- Targeting the MAPK Pathway in KRAS-Driven Tumors
- (2020) Matthias Drosten et al. CANCER CELL
- The Frequency of Ras Mutations in Cancer
- (2020) Ian A. Prior et al. CANCER RESEARCH
- Cancer vaccines: Targeting KRAS-driven cancers
- (2020) Ying Zhang et al. Expert Review of Vaccines
- Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
- (2020) Jay B. Fell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Chelidonine Selectively Inhibits the Growth of Gefitinib-resistant Non-small Cell Lung Cancer Cells through the EGFR-AMPK Pathway
- (2020) Ya-Jia Xie et al. PHARMACOLOGICAL RESEARCH
- EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer
- (2020) Vito Amodio et al. Cancer Discovery
- Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics
- (2020) Naiara Santana-Codina et al. Cell Reports
- Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer
- (2020) Junfei Cheng et al. JOURNAL OF MEDICINAL CHEMISTRY
- RAS-targeted therapies: is the undruggable drugged?
- (2020) Amanda R. Moore et al. NATURE REVIEWS DRUG DISCOVERY
- Dolutegravir derivative inhibits proliferation and induces apoptosis of non-small cell lung cancer cells via calcium signaling pathway
- (2020) Wen-Jun Wang et al. PHARMACOLOGICAL RESEARCH
- An in vivo KRAS allelic series reveals distinct phenotypes of common oncogenic variants
- (2020) Maria Paz Zafra et al. Cancer Discovery
- Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs
- (2020) Michael J. Bond et al. ACS Central Science
- Recombinant KRAS G12D Protein Vaccines Elicit Significant Anti-Tumor Effects in Mouse CT26 Tumor Models
- (2020) Yuhua Wan et al. Frontiers in Oncology
- KRAS: From undruggable to a druggable Cancer Target
- (2020) Dipesh Uprety et al. CANCER TREATMENT REVIEWS
- Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
- (2020) Dongsung Kim et al. CELL
- Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling
- (2020) Huai-Xiang Hao et al. CLINICAL CANCER RESEARCH
- Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer
- (2020) Yuta Adachi et al. CLINICAL CANCER RESEARCH
- SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
- (2020) Carmine Fedele et al. JOURNAL OF EXPERIMENTAL MEDICINE
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition
- (2020) Marco H Hofmann et al. Cancer Discovery
- AIScaffold: A Web-Based Tool for Scaffold Diversification Using Deep Learning
- (2020) Junyong Lai et al. Journal of Chemical Information and Modeling
- Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics
- (2020) Hao Chen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction
- (2019) Roman C. Hillig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience
- (2019) Badi El Osta et al. Journal of Thoracic Oncology
- Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer
- (2019) Elaine Lai-Han Leung et al. INTERNATIONAL JOURNAL OF CANCER
- KRASG12C inhibition produces a driver-limited state revealing collateral dependencies
- (2019) Kevin Lou et al. Science Signaling
- Cordycepin Inhibits Drug-resistance Non-small Cell Lung Cancer Progression by Activating AMPK Signaling Pathway
- (2019) Chunli Wei et al. PHARMACOLOGICAL RESEARCH
- RAS mutations in human cancers: Roles in precision medicine
- (2019) Avaniyapuram Kannan Murugan et al. SEMINARS IN CANCER BIOLOGY
- Glutamine as an Essential Amino Acid for KRas-Driven Cancer Cells
- (2019) Elyssa Bernfeld et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe
- (2019) Nicolas Bery et al. Nature Communications
- Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
- (2019) Miriam Molina-Arcas et al. Science Translational Medicine
- FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
- (2019) Carlos J Diaz Osterman et al. eLife
- Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition
- (2019) Meagan B. Ryan et al. CLINICAL CANCER RESEARCH
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- A view on drug resistance in cancer
- (2019) Neil Vasan et al. NATURE
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- DeepScaffold: A Comprehensive Tool for Scaffold-Based De Novo Drug Discovery Using Deep Learning
- (2019) Yibo Li et al. Journal of Chemical Information and Modeling
- Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
- (2019) Brian A. Lanman et al. JOURNAL OF MEDICINAL CHEMISTRY
- Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS G12C-Driven Mouse Model of Lung Cancer
- (2018) Shuai Li et al. CLINICAL CANCER RESEARCH
- Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer
- (2018) Hayley J. Donnella et al. Nature Chemical Biology
- Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and redox capacity
- (2018) Xing-Xing Fan et al. PHARMACOLOGY & THERAPEUTICS
- Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity
- (2018) Elaine Lai Han Leung et al. Cell Death & Disease
- CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Thanyanan Reungwetwattana et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
- (2018) Sandra Misale et al. CLINICAL CANCER RESEARCH
- Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer
- (2018) Khyati N. Shah et al. NATURE MEDICINE
- Therapeutic strategies to target RAS-mutant cancers
- (2018) Meagan B. Ryan et al. Nature Reviews Clinical Oncology
- Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells
- (2017) Chun Xie et al. Frontiers in Pharmacology
- Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer
- (2016) K.-J. Tang et al. CLINICAL CANCER RESEARCH
- Recent Advances in Scaffold Hopping
- (2016) Ye Hu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
- (2016) Hong Jiang et al. NATURE MEDICINE
- Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
- (2016) Jonathan M. L. Ostrem et al. NATURE REVIEWS DRUG DISCOVERY
- Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
- (2016) P. Lito et al. SCIENCE
- Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
- (2016) M. P. Patricelli et al. Cancer Discovery
- Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
- (2015) Alan Serrels et al. CELL
- Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs
- (2014) M Saqcena et al. ONCOGENE
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More